JD HEALTH
06618
BIDU-SW
09888
JD-SW
09618
ALI HEALTH
00241
BEKE-W
02423
(Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -2.26%536.64B | -2.56%356.01B | 0.18%176.9B | 5.08%755.65B | 1.30%549.03B | 0.69%365.35B | 2.61%176.59B | 5.32%719.08B | 4.99%542B | 6.97%362.85B |
Operating income | -2.26%536.64B | -2.56%356.01B | 0.18%176.9B | 5.08%755.65B | 1.30%549.03B | 0.69%365.35B | 2.61%176.59B | 5.32%719.08B | 4.99%542B | 6.97%362.85B |
Cost of sales | ---- | 3.39%-314.41B | ---- | -4.05%-661.12B | ---- | -0.09%-325.44B | ---- | -6.21%-635.39B | ---- | -7.95%-325.14B |
Operating expenses | 2.51%-474.73B | 3.39%-314.41B | 0.13%-155.86B | -4.05%-661.12B | -1.16%-486.97B | -0.09%-325.44B | -2.65%-156.05B | -6.21%-635.39B | -5.45%-481.37B | -7.95%-325.14B |
Gross profit | -0.23%61.91B | 4.23%41.6B | 2.48%21.05B | 12.95%94.53B | 2.35%62.05B | 5.81%39.91B | 2.36%20.54B | -0.98%83.69B | 1.51%60.63B | -0.78%37.72B |
Selling expenses | -24.13%-2.07B | -43.78%-1.4B | -43.27%-723.87M | -25.95%-2.54B | -30.88%-1.66B | -31.31%-973M | -54.69%-505.25M | -39.15%-2.02B | -20.31%-1.27B | -8.65%-741M |
Administrative expenses | 1.45%-12.14B | -2.97%-18.91B | -3.49%-4.4B | -7.81%-47.59B | -2.27%-12.32B | -3.81%-18.37B | 1.27%-4.26B | -2.98%-44.14B | 8.58%-12.05B | 3.50%-17.69B |
Research and development expenses | -0.74%-17.44B | ---- | 6.92%-4.69B | ---- | -0.84%-17.31B | ---- | -11.75%-5.04B | ---- | -10.08%-17.17B | ---- |
Profit from asset sales | -31.75%245.52M | ---- | 10.58%13.15M | ---- | 116.39%359.75M | ---- | -86.35%11.9M | ---- | 152.40%166.25M | ---- |
Revaluation surplus | 79.46%-144.12M | ---- | 110.91%5.11M | ---- | -1,003.46%-701.51M | ---- | -236.26%-46.84M | ---- | -47.96%77.65M | ---- |
-Changes in the fair value of other assets | 79.46%-144.12M | ---- | 110.91%5.11M | ---- | -1,003.46%-701.51M | ---- | -236.26%-46.84M | ---- | -47.96%77.65M | ---- |
Impairment and provision | -4.75%-3.08B | 24.15%-2.17B | 125.15%118.84M | 18.84%-7.9B | 15.79%-2.94B | -2.84%-2.87B | -1,127.54%-472.43M | -40.15%-9.74B | -142.48%-3.49B | -72.61%-2.79B |
-Other impairment is provision | -4.75%-3.08B | 24.15%-2.17B | 125.15%118.84M | 18.84%-7.9B | 15.79%-2.94B | -2.84%-2.87B | -1,127.54%-472.43M | -40.15%-9.74B | -142.48%-3.49B | -72.61%-2.79B |
Special items of operating profit | 793.37%1.25B | -30.67%1.41B | 94.14%-15.74M | -60.36%2.46B | -89.14%140.26M | -55.41%2.04B | 35.11%-268.77M | 386.13%6.2B | 452.50%1.29B | 326.80%4.57B |
Adjustment items of operating profit | ---- | ---- | --1 | ---- | ---- | ---- | ---- | ---- | --1 | ---- |
Operating profit | 2.18%26.91B | 3.97%20.53B | 13.17%10.8B | 14.57%38.96B | -0.43%26.33B | -6.30%19.74B | -4.25%9.54B | -1.56%34B | -4.13%26.45B | 14.16%21.07B |
Financing income | ---- | -3.17%10.7B | ---- | 12.08%23.9B | ---- | 29.72%11.05B | ---- | 45.94%21.32B | ---- | 22.54%8.52B |
Financing cost | -28.07%-1.3B | -1.27%-11.65B | -37.43%-1.48B | -10.95%-24.31B | 42.73%-1.02B | -10.75%-11.5B | 45.19%-1.07B | -12.13%-21.91B | 62.67%-1.77B | -12.34%-10.39B |
Share of profits of associates | ---- | 33.49%291M | ---- | 18.37%406M | ---- | 216.58%218M | ---- | -56.58%343M | ---- | -1,435.71%-187M |
Share of profit from joint venture company | ---- | -25.31%-896M | ---- | -111.56%-1.41B | ---- | -14.40%-715M | ---- | -8.47%-666M | ---- | -129.78%-625M |
Special items of earning before tax | -88.52%-23.14M | ---- | -190.23%-27.52M | ---- | -120.24%-12.27M | ---- | -16.36%30.5M | ---- | -74.52%60.64M | ---- |
Adjustment items of earning before tax | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---1 | ---- |
Earning before tax | 1.09%25.58B | 0.95%18.97B | 9.38%9.3B | 13.45%37.54B | 2.31%25.31B | 2.18%18.79B | 5.66%8.5B | 11.08%33.09B | 7.19%24.73B | 15.63%18.39B |
Tax | -3.26%-4.59B | -18.30%-3.81B | -13.56%-1.77B | 10.12%-6.4B | 10.91%-4.45B | 19.42%-3.22B | 9.15%-1.56B | -20.06%-7.12B | -12.36%-4.99B | -34.26%-4B |
After-tax profit from continuing operations | 0.63%20.99B | -2.64%15.16B | 8.44%7.53B | 19.91%31.14B | 5.65%20.86B | 8.19%15.57B | 9.68%6.94B | 8.85%25.97B | 5.96%19.74B | 11.33%14.39B |
After-tax profit from non-continuing business | ---- | ---- | --0 | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
Special items of earning after tax | ---- | ---- | ---- | ---- | ---1 | ---- | ---1 | ---- | ---- | ---- |
Adjustment items of earning after tax | ---- | ---- | ---- | ---- | --1 | ---- | --1 | ---- | ---- | ---- |
Earning after tax | 0.63%20.99B | -2.64%15.16B | 8.44%7.53B | 19.91%31.14B | 5.65%20.86B | 8.19%15.57B | 9.68%6.94B | 8.85%25.97B | 5.96%19.74B | 11.33%14.39B |
Minority profit | 5.16%4.72B | -0.63%3.13B | 2.03%1.39B | 11.52%6.41B | 14.78%4.49B | 30.34%3.15B | 10.03%1.36B | 4.26%5.75B | 6.53%3.91B | -4.69%2.42B |
Adjustment items of profit attributable to shareholders | ---- | ---- | ---- | ---- | --1 | ---- | ---- | ---- | ---- | ---- |
Profit attributable to shareholders | -0.61%16.27B | -3.15%12.02B | 10.00%6.14B | 22.29%24.73B | 3.39%16.37B | 3.71%12.41B | 9.60%5.58B | 10.23%20.23B | 5.82%15.84B | 15.24%11.97B |
Basic earnings per share | -4.11%0.7 | 12.50%0.36 | 26.09%1.45 | 4.29%0.73 | 10.34%0.32 | 10.58%1.15 | 5.81%0.91 | 16.67%0.7 | ||
Diluted earnings per share | -4.11%0.7 | 12.50%0.36 | 26.09%1.45 | 4.29%0.73 | 10.34%0.32 | 10.58%1.15 | 5.81%0.91 | 16.67%0.7 | ||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
Auditor | -- | -- | -- | Ernst & Young Huaming (Special General Partnership), Ernst & Young | -- | -- | -- | Ernst & Young Huaming (Special General Partnership), Ernst & Young | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.